Immune Checkpoint Inhibitors in Geriatric Oncology
SL Cook, M Al Amin, S Bari, PJ Poonnen… - Current Oncology …, 2024 - Springer
Abstract Purpose of Review This manuscript will update prior reviews of immune checkpoint
inhibitors (ICIs) in light of basic science, translational, and clinical discoveries in the field of …
inhibitors (ICIs) in light of basic science, translational, and clinical discoveries in the field of …
PHF23 promotes NSCLC proliferation, metastasis, and chemoresistance via stabilization of ACTN4 and activation of the ERK pathway
M Cheng, H Cao, P Yao, J Guan, P Wu, H Ji… - Cell Death & …, 2023 - nature.com
At present, non-small cell lung cancer (NSCLC) is still one of the leading causes of cancer-
related deaths. Chemotherapy remains the standard treatment for NSCLC. However, the …
related deaths. Chemotherapy remains the standard treatment for NSCLC. However, the …
Overall Survival after Radiotherapy for Brain Metastases According to ECOG Status—A Prospective Study of 294 NSCLC Patients
AT Karlsson, MJ Hjermstad, N Aass, E Skovlund… - Cancers, 2024 - mdpi.com
Simple Summary Non-smallcell lung cancer patients frequently develop brain metastases.
Most patients are treated with radiotherapy, but the potential benefit from radiotherapy in …
Most patients are treated with radiotherapy, but the potential benefit from radiotherapy in …
PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cells in lung cancer brain metastasis.
J Blobner, L Dengler, C Eberle, JJ Herold, T Xu, A Beck… - 2024 - researchsquare.com
Background Lung cancer brain metastasis have a devastating prognosis, necessitating
innovative treatment strategies. While chimeric antigen receptor (CAR) T-cells show promise …
innovative treatment strategies. While chimeric antigen receptor (CAR) T-cells show promise …